Eukaryote

Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma

Retrieved on: 
Wednesday, August 10, 2022 - 6:00am

The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.

Key Points: 
  • The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.
  • Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization.
  • In the CT-01 project, we are entering the advanced stage of preclinical development of the drug candidate, i.e.
  • Captor is progressing according to plan and will deliver on its promises to enter the clinical phase in 2023.

The Root Brands Releases its 7th product Mitochondria Defense Shield with NAD

Retrieved on: 
Saturday, August 6, 2022 - 1:24am

Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.

Key Points: 
  • Mitochondria Defense Shield, MDS, is a patent pending proprietary combination of vitamins, minerals, flavonoids, and enzymes working together to maintain DNA integrity and ensure proper cell function, to protect your body from aging and disease.
  • Mitochondria are tiny double membrane-bound organelles found in almost every cell of all organisms except bacteria, they are known as "the powerhouse of the cell".
  • It enters the mitochondria in its oxidized form and protects mitochondria from oxidative injury.
  • Vitamin D is vital for regulating the absorption of calcium and phosphorus and facilitating normal immune system function.

OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

Retrieved on: 
Wednesday, June 15, 2022 - 1:00pm

OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.

Key Points: 
  • OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.
  • The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
  • Once we clinically validate the technology, we plan to expand the indications of treatments to various non-hereditary eye diseases as well.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

Advances for India as foundational CRISPR/Cas9 gene editing patent granted

Retrieved on: 
Monday, June 13, 2022 - 8:00am

This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.

Key Points: 
  • This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to this foundational CRISPR/Cas9 intellectual property.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: "This is a strong statement for India.
  • Technological advances have long been a national priority, and this is globally recognized with India among the top 12 destinations for biotechnology worldwide.

Advances for India as foundational CRISPR/Cas9 gene editing patent granted

Retrieved on: 
Monday, June 13, 2022 - 8:00am

This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.

Key Points: 
  • This patentcovers methods and compositions for use of CRISPR/Cas9 and chimeric Cas9 in all cell types including eukaryotic cells.
  • ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to this foundational CRISPR/Cas9 intellectual property.
  • Michael Arciero, Vice-President of Intellectual Property and Commercial Development, ERS Genomics, said: "This is a strong statement for India.
  • Technological advances have long been a national priority, and this is globally recognized with India among the top 12 destinations for biotechnology worldwide.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022 - 8:00am

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Patent upheld, ERS leadership position in European CRISPR Landscape confirmed

Retrieved on: 
Tuesday, May 31, 2022 - 8:00am

DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.

Key Points: 
  • DUBLIN, May 31, 2022 /PRNewswire/ -- The Opposition Division of the European patent office has maintained European Patent Number 3401400 over challenges from several groups, reinforcing this strong foundational CRISPR patent in Europe.
  • European Patent 3401400 ('EP400') has withstood formal opposition at the European Patent Office ('EPO') with only minor modifications.The decision by the EPO Opposition Division ('OD') was recently published following lengthy hearings which concluded in February of this year.
  • The patent is jointly owned by ERS founder and Nobel prize winner Dr. Emmanuelle Charpentier, along with the University of Vienna and the University of California (jointly known as the 'CVC' group).
  • Opponents had challenged EP400 at the European Patent Office formally claiming lack of novelty and inventive step and asking the OD to revoke the patent in its entirety.

Metagenomi Presents Findings on Novel Families of Ultra Small, CRISPR Enzymes at the Keystone Symposia Precision Genome Engineering Conference

Retrieved on: 
Tuesday, May 3, 2022 - 1:00pm

Metagenomi , a genetic medicines company with a versatile portfolio of next-generation gene editing tools, presented findings on the identification of novel families of compact, programmable enzymes for genome editing at the Keystone Symposia Precision Genome Engineering and Emerging Cellular Therapies Conference, on April 30.

Key Points: 
  • Metagenomi , a genetic medicines company with a versatile portfolio of next-generation gene editing tools, presented findings on the identification of novel families of compact, programmable enzymes for genome editing at the Keystone Symposia Precision Genome Engineering and Emerging Cellular Therapies Conference, on April 30.
  • The presentation described SMART (SMall ARchaeal-associaTed) systems that were mined from Metagenomis proprietary metagenomics database of novel nucleases found from natural environments.
  • They are also found naturally on humans; however, to date, no Archaea have been characterized as a human pathogen.
  • The gene editing activity of these systems was demonstrated in E. coli and reconstitution of the SMART systems in vitro displayed novel biochemical characteristics.

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Retrieved on: 
Thursday, April 21, 2022 - 1:30pm

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Key Points: 
  • In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.
  • Octant also plans to develop multiple additional therapeutic programs in small molecule chaperone therapies for rare genetic diseases.
  • Immunogenetics and immunopharmacology are among the most complex areas in biology and drug discovery, with potential to impact countless patients, continued Kosuri.
  • As Chief Scientific Officer, Rick Artis will be responsible for Octant's chemistry function and drug discovery and development programs.

Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma

Retrieved on: 
Tuesday, April 12, 2022 - 6:00am

"The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.

Key Points: 
  • "The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.
  • Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023.
  • Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
  • Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.